JP2016540050A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540050A5
JP2016540050A5 JP2016555933A JP2016555933A JP2016540050A5 JP 2016540050 A5 JP2016540050 A5 JP 2016540050A5 JP 2016555933 A JP2016555933 A JP 2016555933A JP 2016555933 A JP2016555933 A JP 2016555933A JP 2016540050 A5 JP2016540050 A5 JP 2016540050A5
Authority
JP
Japan
Prior art keywords
amino acid
moiety
seq
acid residues
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555933A
Other languages
English (en)
Japanese (ja)
Other versions
JP6792452B2 (ja
JP2016540050A (ja
Filing date
Publication date
Priority claimed from GBGB1321242.8A external-priority patent/GB201321242D0/en
Application filed filed Critical
Publication of JP2016540050A publication Critical patent/JP2016540050A/ja
Publication of JP2016540050A5 publication Critical patent/JP2016540050A5/ja
Application granted granted Critical
Publication of JP6792452B2 publication Critical patent/JP6792452B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555933A 2013-12-02 2014-12-02 免疫原性化合物 Expired - Fee Related JP6792452B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1321242.8 2013-12-02
GBGB1321242.8A GB201321242D0 (en) 2013-12-02 2013-12-02 Immunogenic compound
PCT/GB2014/053577 WO2015082905A1 (en) 2013-12-02 2014-12-02 Immunogenic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020185572A Division JP7095053B2 (ja) 2013-12-02 2020-11-06 免疫原性化合物

Publications (3)

Publication Number Publication Date
JP2016540050A JP2016540050A (ja) 2016-12-22
JP2016540050A5 true JP2016540050A5 (https=) 2018-01-25
JP6792452B2 JP6792452B2 (ja) 2020-11-25

Family

ID=49979653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016555933A Expired - Fee Related JP6792452B2 (ja) 2013-12-02 2014-12-02 免疫原性化合物
JP2020185572A Expired - Fee Related JP7095053B2 (ja) 2013-12-02 2020-11-06 免疫原性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020185572A Expired - Fee Related JP7095053B2 (ja) 2013-12-02 2020-11-06 免疫原性化合物

Country Status (10)

Country Link
US (4) US9962453B2 (https=)
EP (1) EP3077052A1 (https=)
JP (2) JP6792452B2 (https=)
KR (1) KR102356869B1 (https=)
CN (1) CN105873638A (https=)
BR (1) BR112016012528A2 (https=)
CA (1) CA2931933A1 (https=)
EA (1) EA201691146A1 (https=)
GB (1) GB201321242D0 (https=)
WO (1) WO2015082905A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
US11464854B2 (en) * 2017-03-23 2022-10-11 Children's Medical Center Corporation Methods and compositions relating to adjuvants
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
ES2951817T3 (es) 2017-08-22 2023-10-25 Dynavax Tech Corp Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
KR20250078621A (ko) * 2018-07-10 2025-06-02 세퀴러스 피티와이 리미티드 응집체의 제거
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020205996A2 (en) * 2019-04-01 2020-10-08 Altimmune Uk Ltd Locally acting toll-like receptor 7 (tlr7) and/or tlr8 agonist immunotherapy compounds and their uses
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines
US20250360205A1 (en) * 2022-06-09 2025-11-27 Academia Sinica Nod1 modulators and uses thereof
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
KR102784104B1 (ko) * 2024-04-04 2025-03-24 대한민국(방위사업청장) 이미퀴모드 및 Nod2 수용체 자극 성분 또는 박테리아를 포함하는 면역 어쥬번트

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294605A (en) 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
FR2744123B1 (fr) * 1996-01-26 1998-04-17 Carelli Claude Marcel Henri Molecules biologiquement actives plus particulierement peptidiques ayant un effet potentialisateur de l'activite biologique de l'hormone de croissance
ES2312659T3 (es) 2001-11-29 2009-03-01 3M Innovative Properties Company Formulaciones farmaceuticas que comprenden un modificador de la respuesta inmune.
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
CA2605808A1 (en) 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
TR201802083T4 (tr) 2008-10-24 2018-03-21 Glaxosmithkline Biologicals Sa Lipidatlı imidazokinolin türevleri.
EP2387421A1 (en) * 2009-01-14 2011-11-23 SKU Asset Management GmbH Compounds comprising n-formyl-methionine residues and tumor-targeting peptides
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体(tlr)を介して作用するイミダゾキノリン
US8916162B2 (en) 2010-02-20 2014-12-23 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
WO2012113413A1 (en) * 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ2官能性リンカー及び該リンカーから調製された免疫反応調節複合体
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound

Similar Documents

Publication Publication Date Title
JP2016540050A5 (https=)
JP7095053B2 (ja) 免疫原性化合物
CN103402539B (zh) 一种用于产生对抗病原体的持久免疫和保护的合成免疫原
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
KR102239207B1 (ko) 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법
CN110279853A (zh) 包含聚合载体货物复合物和至少一种蛋白或肽抗原的药物组合物
Keijzer et al. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion
JP2011525190A (ja) インフルエンザを処置するための組成物および方法
EP3790581A1 (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
AU2006236294A1 (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
JP7561182B2 (ja) ペプチドがロードされたキャリアシステムおよびその使用
Tohumeken et al. A modular antigen presenting peptide/oligonucleotide nanostructure platform for inducing potent immune response
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
US20230109142A1 (en) Corona virus vaccine
HK1130687A (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease